Table 1: Patient characteristics.
N = 33 |
|
Age (years) |
64.6 ± 9.2 (38-82) |
Male patients |
30 (90%) |
Duration of AA (years) |
1.6 ± 1.3 |
BMI (kg/m2) |
24.6 ± 3.5 |
CHADS2 score |
1.6 ± 0.7 |
Echo parameters at baseline |
|
LVEF (%) |
30.7 ± 10.9 |
LAD (mm) |
45.1 ± 5.5 |
LVDd (mm) |
54.8 ± 7.3 |
LVDs (mm) |
46.5 ± 8.0 |
LVEDV (ml) |
118.2 ± 37.7 |
LVESV (ml) |
80.8 ± 32.4 |
Enlarged LVDd > 60 mm |
7 (21%) |
Drugs |
|
AAD |
24 (73%) |
Diuretic |
15 (45%) |
Beta blocker |
31 (94%) |
ACEI |
20 (%) |
DOAC |
31 (94%) |
Warfarin |
2 (6%) |
Continuous variables are shown as mean ± SD.
AA: Atrial Arrhythmia; BMI: Body Mass Index; LVEF: Left Ventricular Ejection Fraction; LAD: Left Atrial Dimension; Lvdd: Left Ventricular End-Diastolic Dimension; Lvds: Left Ventricular End-Systolic Dimension; LVEDV: Left Ventricular End-Diastolic Volume; LVESV: Left Ventricular End-Systolic Volume; AAD: Anti-Arrhythmic Drug; ACEI: Angiotensin-Converting Enzyme Inhibitor; DOAC: Direct Oral Anticoagulant